© 2007 European Society for Medical Oncology
symposium article |
The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006
1 Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium
2 Department of Haematology-Oncology, Luxembourg Medical Center, Luxembourg, Luxembourg
3 Medical Oncology, University of Marche, Umberto I Hospital, Ancona, Italy
4 Department of Medical Oncology, The Royal Marsden Hospital, Surrey, UK
5 Department of Medical Oncology, San Carlos Hospital Clinic, Madrid, Spain
6 Department of Oncology, Radiology and Clinical Immunology, University of Uppsala, Uppsala and Karolinska Institutet, Stockholm, Sweden
7 University of Pennsylvania Cancer Center, Philadelphia, PA, USA
8 Medizinische Klinik and Poliklinik III, University of Munich, Munich, Germany
9 Department of Gastrointestinal Medical Oncology, Hospital Sirio-Libanes, Sao Paulo, Brazil
10 Centre for Cancer Research & Cell Biology, Queen's University Belfast, Northern Ireland
11 Department of Clinical Pharmacology, University of Oxford, Oxford, UK
12 Medical Oncology Unit, Ospedale Riuniti, Bergamo, Italy
13 Department of Oncology, Hôpital Saint-Antoine, Paris, France
14 Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
15 Division of Applied Molecular Oncology, University of Toronto, Toronto, Ontario, Canada
16 Departments of Surgery and Gastroenterology, Hôpital Ambroise Paré, Boulogne, France
17 Department of Medical and Surgical Sciences, University of Padua, Padova, Italy
18 Department of Surgery, Geneva University Hospital, Geneva, Switzerland
19 Division of Oncology, Vanderbilt University Medical Center, Nashville, TN, USA
20 Department of Hematology and Oncology, Martin Luther Universität, Halle, Germany
21 Medical Oncology Service, Vall d'Hebron University Hospital, Barcelona, Spain
22 Division of Medical Oncology, University of California, San Francisco, CA, USA
23 Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
24 Department of Gastroenterology, Erasme University Hospital, Brussels, Belgium
25 Peter MacCallum Cancer Centre and Department of Medicine, University of Melbourne, Melbourne, Australia
* Correspondence to: Dr E. Van Cutsem, Digestive Oncology Unit, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium. Tel: 32-16-34-42-25; Fax: 32-16-34-44-19; E-mail: eric.vancutsem{at}uz.kuleuven.ac.be
This article summarizes the expert discussion on the management of pancreatic cancer, which took place during the 8th World Congress on Gastrointestinal Cancer in June 2006 in Barcelona. A multidisciplinary approach to a patient with pancreatic cancer is essential, in order to guarantee an optimal staging, surgery, selection of the appropriate (neo-)adjuvant strategy and chemotherapeutic choice management. Moreover, optimal symptomatic management requires a dedicated team of health care professionals. Quality control of surgery and pathology is especially important in this disease with a high locoregional failure rate. There is now solid evidence in favour of chemotherapy in both the adjuvant and palliative setting, and gemcitabine combined with erlotinib, capecitabine or platinum compounds seems to be slightly more active than gemcitabine alone in advanced pancreatic cancer. There is a place for chemoradiotherapy in selected patients with locally advanced disease, while the role in the adjuvant setting remains controversial. Those involved in the care for patients with pancreatic cancer should be encouraged to participate in well-designed clinical trials, in order to increase the evidence-based knowledge and to make further progress.
Key words: adjuvant treatment, chemotherapy, pancreatic cancer, radiotherapy
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Van Cutsem, W. L. Vervenne, J. Bennouna, Y. Humblet, S. Gill, J.-L. Van Laethem, C. Verslype, W. Scheithauer, A. Shang, J. Cosaert, et al. Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer J. Clin. Oncol., May 1, 2009; 27(13): 2231 - 2237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Iacobuzio-Donahue, B. Fu, S. Yachida, M. Luo, H. Abe, C. M. Henderson, F. Vilardell, Z. Wang, J. W. Keller, P. Banerjee, et al. DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer J. Clin. Oncol., April 10, 2009; 27(11): 1806 - 1813. [Abstract] [Full Text] [PDF]
|
|